Tenpoint and Visus Merge to Advance Eye Care

Tenpoint Therapeutics Ltd. and Visus Therapeutics Inc. have officially merged, combining their respective ophthalmic therapeutic assets to form a unified entity focused on addressing ocular conditions associated with aging, including presbyopia, cataracts, and geographic atrophy.

Key Therapeutics in the Combined Portfolio

BRIMOCHOL PF: A Promising Presbyopia Treatment

A cornerstone of the merged portfolio is BRIMOCHOL PF, an innovative, once-daily eye drop for correcting presbyopia. The therapy combines:

• Carbachol: A miotic agent.

• Brimonidine: An alpha2-agonist.

This combination is designed to improve efficacy and duration while minimizing ocular redness. BRIMOCHOL PF is slated for a New Drug Application (NDA) submission in the first half of 2025, with U.S. commercialization planned by 2026.

Additional Therapeutic Programs from Tenpoint

The merger also incorporates Tenpoint’s advanced-stage programs:

• TPT-161: A small molecule targeting cataract formation.

• TPT-005: A cell therapy for retinal pigment epithelium (RPE) replacement to treat geographic atrophy.

Leadership Team

Henric Bjarke, CEO

Henric Bjarke has been appointed as CEO of the combined company. With extensive leadership experience in biopharmaceuticals, particularly in ophthalmology, Bjarke expressed enthusiasm for the newly merged entity:

“As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with BRIMOCHOL PF, a near-term therapeutic medicine for presbyopia, alongside other innovative therapies to treat cataract and geographic atrophy. With our combined teams, we have the right expertise to develop and successfully launch innovative products with the potential to be first and best in class in ophthalmic medicines.”

David Guyer, MD, Chairman of the Board

Dr. David Guyer will serve as Chairman of the Board, bringing significant expertise to the company’s strategic direction:

“The merger of Tenpoint and Visus is a pivotal moment in the evolution of both companies. As Board Chair, I am excited about the opportunity to collaborate with the new leadership team to commercialize BRIMOCHOL PF and advance innovative products into clinical development to meet unmet needs in ocular diseases.”

Financial and Strategic Plans

The company plans to initiate a crossover financing round to support ongoing clinical studies and prepare for the commercialization of BRIMOCHOL PF.

Consolidated Mission and Future Goals

By merging late-stage and early-stage programs, the combined company aims to:

• Advance BRIMOCHOL PF and additional therapies through clinical and regulatory milestones.

• Address critical unmet needs in ocular conditions related to aging.

• Plan for the introduction of innovative ophthalmic treatments to the market.

This merger represents a transformative step for both companies, uniting their strengths to drive innovation and deliver cutting-edge solutions in ophthalmology.